HER2抗体-纳米凝结合物:一种高容量,抗体节约的替代抗体-药物结合物的替代品
Jingyi Qiu1,2, Yasin Alp2,3, Shuai Gong2,3
1Department of Biomedical Engineering, University of Massachusetts, Amherst, Massachusetts 01003, United States.
Nano letters
|December 23, 2025
概括
针对HER2的新抗体-纳米凝结合物 (ANCs) 显示出强大的乳腺癌细胞杀伤和体内疗效,使用的抗体明显少于目前的治疗方法.
科学领域:
- 在瘤学瘤学.
- 纳米技术 纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗体-药物合物 (ADC) 在向癌症治疗中至关重要.
- 卡德西拉 (T-DM1) 是一种经过临床批准的针对HER2的ADC.
- 开发ADC面临诸如有效载荷修改和药物对抗体比率 (DAR) 等挑战.
研究的目的:
- 开发和评估新的HER2向抗体-纳米凝结合物 (ANCs) 与封装的DM1.
- 为了对ANC与已确定的ADC进行基准测试,T-DM1.1.
- 评估ANC作为下一代治疗平台的潜力.
主要方法:
- 合成HER2向抗体-纳米凝结合物 (ANCs) 与共封装的DM1.
- 在体外细胞毒性测试中比较ANC和T-DM1.
- 在BT-474乳腺癌异种移植模型中的体内疗效研究.
主要成果:
- 在体外,ANCs表现出与T-DM1.1相比的细胞毒性.
- 在体内,HER2-DM1-ANC获得了与T-DM1.1相比4倍少的抗体,具有相当的抗瘤疗效.
- 在没有有效载荷修改的情况下,ANC显示了更高的药物对抗体比率.
结论:
- 抗体导向治疗的ANC是一个有前途的,高容量的纳米凝平台.
- 减少ANC抗体的需求可能会减轻耐药性,并提供一个关键的优势.
- 在癌症治疗中,ANCs对未来的改进和优化具有显著的潜力.
更多相关视频
08:09Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy
Published on: April 6, 2015
12.1K
11:02Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
8.1K
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:31Hybridoma Technology
17.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.1K